Skip to main content
. 2026 Nov 16. Online ahead of print. doi: 10.1039/d6ra09748k

Table 2. Comparative analytical characteristics and validation evidence of GQD–Au-containing platforms for the detection of cancer biomarkers and cellsa.

Target Architecture and readout Calibration and detection evidence Selectivity and sample-matrix evidence Additional analytical evidence Ref.
PCA3-associated target DNA Au–GQD-modified ITO; DNA hybridization monitored by CV Reported range: 100 fM–1 µM; LOD: 211 fM CYFRA-21 and cardiac-troponin-I DNA examined individually and with the target; measurements performed in PBS/ferro–ferricyanide electrolyte Experiments performed using different electrodes, n = 3; response time reported as 5 min, while optimization text describes saturation after 10 min; shelf life approximately 19 ± 1 days 76
miRNA-21, miRNA-155, and miRNA-210 AuNPs/GQDs/GO on a three-electrode array; multiplexed SWV Range: 0.001–1000 pM for each target; respective LODs: 0.04, 0.33, and 0.28 fM Single-base and triple-base mismatches, non-complementary sequences, and cross-channel interference examined; human-serum application Respective inter-electrode RSDs: 8.40%, 4.51%, and 9.43%, using 15 fabricated electrodes; target hybridization: 60 min; fabrication plus determination: 4 h 30 min; respective response retention after 21 days at 4 °C: 84.3%, 85.9%, and 89.5% 77
Glioma cells Ang-2-conjugated S-GQDs@Au–carbon nanospheres; pulse-assisted EIS Range: 100–100 000 cells mL−1; LOD: 40 cells mL−1 Selective glioma-cell detection demonstrated in a human-serum matrix; this matrix experiment should not be interpreted as evidence of patient-derived circulating-tumor-cell detection An external +0.6 V pulse promotes cell attachment to the recognition interface; the reported analytical performance therefore incorporates electrically assisted capture 87
PSA S-GQDs/gold nanostars on a screen-printed electrode; LSV immunosensing PBS range: 10 fg mL−1–50 ng mL−1; serum range: 100 fg mL−1–35 ng mL−1; respective LODs: 0.29 and 26 fg mL−1 Discrimination against eight interferents; measurements in PBS and neat human serum Human-serum recovery: 97–107%; the serum LOD is approximately 90 times higher than the buffer LOD, demonstrating substantial matrix dependence 78
CD44 Exfoliated GQDs decorated with AuNPs; antibody-based electrochemical sensing LOD: 1.17 fg mL−1 in PBS Anti-CD44 immobilization through EDC/NHS coupling; analytical detection demonstrated in PBS Electrochemical exfoliation provides GQDs with an approximate diameter of 3 nm, combined with approximately 15 nm AuNPs; the reported detection limit represents buffer-based performance 79
HepG2 cells Folic-acid/glutamic-acid-functionalized GQDs–Pd@Au; electrochemical cytosensing Cell-dependent electrochemical detection using a recognition-active and catalytically amplified hybrid Folic-acid-mediated cancer-cell recognition; application to human blood Glutamic-acid functionalization supports electrochemical activity, while Pd@Au contributes catalytic amplification; the measured response reflects the complete multicomponent architecture 89
CEA N,S-GQDs/gold nanostars; wash-free fluorescence-recovery immunoassay Dynamic range: 0.1 pg mL−1–10 µg mL−1; LOD: 64 fg mL−1 Common ions, amino acids, and PSA examined; human-serum application Human-serum recovery: 93–106%; wash-free fluorescence recovery provides a solution-phase assay format; stability and reproducibility were examined in the original study 84
CEA AuNPs/N-GQDs/rGO; label-free DPV immunosensing Range: 1 pg mL−1–500 ng mL−1; LOD: 0.13 pg mL−1 PSA, AFP, NGAL, CA19-9, CA125, and additional interferents examined; tenfold interference challenge; fetal bovine serum diluted 50-fold Calibration slope: −1.73 ± 0.054 µA per decade of concentration; inter-electrode RSD: 1.8%, n = 5; CEA incubation: 45 min in optimization study; 93.5% response retained after 5 days at 4 °C; serum recovery: 101–103% 81
CEA N,S-GQDs/Au–polyaniline nanowires; EIS immunosensing Range: 0.5–1000 ng mL−1, calibrated against logarithmic concentration; LOD: 0.01 ng mL−1 AFP, Tau, haemoglobin, l-cysteine, and l-glutamate examined; combined interference mixture increased response by approximately 11.4%; human serum diluted 10-fold Inter-electrode RSD: 6.8%, n = 5; antigen incubation: 60 min at room temperature; response retained at 4 °C: 98% ± 3%, 92% ± 4%, and 87% ± 4% after 10, 15, and 20 days, respectively; serum recovery: approximately 96.0–103.1% 80
p53 Poly-l-cysteine/GQDs/AuNP multilayer interface; SWV and DPV immunosensing SWV range: 0.000197–0.016 pM; DPV range: 0.195–50 pM; plasma range: 0.000592–1.296 pM; lower quantification limit: 0.065 fM Measurements in unprocessed human plasma and normal/malignant cell lysates Different calibration intervals were established for SWV, DPV, and plasma measurements; 0.065 fM is retained as a quantification threshold rather than being reclassified as an LOD 82
CA 15-3-associated immunoreactivity Gold nanospears assembled onto thiolated GQDs; SWV immunoassay Range: 0.16–125 U mL−1; reported detectable concentration: 0.11 U mL−1 Application to unprocessed human plasma and MCF-7 cell lysates SWV monitors antigen–antibody binding at the hybrid interface; the conservative target designation accommodates inconsistent antigen/antibody terminology 83
CEA GQDs@AuNP-labelled secondary antibody with a P5FIn/erGO capture interface; ECL Range: 0.1 pg mL−1–10 ng mL−1; LOD: 3.78 fg mL−1 Human-serum recovery testing; selectivity evaluated Reproducibility and stability evaluated; analytical amplification combines the P5FIn/erGO capture interface with GQDs@AuNP-labelled secondary antibodies 86
CEA Hydrazide-modified GQD–AuNP hybrids on glassy carbon; ECL immunosensing CEA-dependent ECL attenuation following immunoreaction Antibody–antigen recognition at the modified electrode Hybrid formation combines the ECL properties of hydrazide-modified GQDs with the biomolecular assembly capability of AuNPs; the response is interpreted through recognition-induced changes at the electrode interface 85
Glioma cells Ang-2/GQDs–nanoporous gold; label-free EIS Range: 1–106 cells mL−1; LOD: 1 cell mL−1 Anti-interference against multiple cell lines; spiked human-serum testing Response retention: 96% after 21 days of storage; measured cell concentrations in serum agreed with the added concentrations 88
CA-125 MXene/GQD/AuNP-modified GCE; electrochemical immunosensing Reported range: 0.1–1 nU mL−1; LOD: 0.075 nU mL−1; units retained as reported Real-sample testing and selectivity assessment CV, EIS, SWV, and DPV characterization; reproducibility evaluated 102
HER2 Gold-functionalized S,N-GQDs, cobalt porphyrin framework, and their conjugate; EIS immunosensing Three investigated interfaces gave LODs of 0.0327, 0.0454, and 0.1072 ng mL−1 Antibody-mediated recognition; human-serum application Formulation comparison; stability and reproducibility evaluated 103
HER2 Gold-functionalized GQD/porphyrin interfaces bearing aptamer or antibody; EIS Comparative detection performance of alternative recognition elements Spiked human serum Aptasensors showed improved detection limits, reusability, and storability relative to the corresponding immunosensors 104
PSA PANI/GQD/WOx/Au on graphenized screen-printed carbon electrode; PEC immunosensing Range: 0.1 pg mL−1–100 ng mL−1; LOD: 75 fg mL−1 Human serum without dilution or deproteinization Co-electrodeposition followed by AuNP modification; illumination-dependent photocurrent transduction 105
Glycan-overexpressing cancer cells N-GQD-wrapped AuNPs with Raman reporter and boronic-acid targeting ligand; SERS Targeted cell-surface recognition demonstrated by SERS imaging Recognition of glycan-overexpressing cancer cells Electromagnetic and chemical enhancement examined using experimental observations and computational modelling 106
MCF-7 cells PHAL-functionalized N,S-GQD/gold-nanostar interface; electrochemical cytosensing Range: 10–105 cells mL−1; LOD: 3 cells mL−1 Specificity assessed against other cancer-cell types Storage assessments extending to 100 days and reuse assessments extending to 30 cycles 107
BRCA1 AuNP@ZIF-8 capture interface with N-GQD-labelled secondary antibody; DPV Range: 1 pg mL−1–50 ng mL−1; LOD: 0.3 pg mL−1 Interference responses below 5%; spiked-serum recovery: 96.8–104.2% RSD: 3.8%; 92.5% signal retained after 30 days 108
Glioma cells GQD–nanoporous gold nanocomposite Angiopep-2-mediated recognition; label-free impedimetric detection Range: 1–106 cells mL−1; reported LOD: 1 cell mL−1; human serum containing added glioma cells; 96% response retained after 21 days of storage; interference evaluated using other cell lines 88
a

Entries summarize the reported analytical and validation evidence selected for comparison. Sensitivity denotes the calibration slope and is distinguished from LOD and quantification thresholds. Calibration intervals retain their original concentration-linear, logarithmic, or dynamic-range descriptions. Response times refer to the specified assay step; storage retention describes shelf stability and should not be interpreted as operational stability during repeated use. Differences in matrix dilution, electrolyte, electrode configuration, incubation procedures, and calibration models restrict direct comparisons. Accordingly, the table supports condition-dependent assessment rather than an unconditional ranking of sensor performance.